首页> Clinical cancer research : an official journal of the American Association for Cancer Research> Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial.

Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial.

导出 OA

翻译打印收藏纠错

第一作者： Li,Chen

第一单位： Key Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai Medical College of Fudan University, Shanghai, China.;Department of Oncology, Shanghai Medical College of Fudan University, Shanghai, China.

作者： Li,Chen ^[1] ; Yi-Zhou,Jiang ^[1] ; Song-Yang,Wu ^[1] ; Jiong,Wu ^[1] ; Gen-Hong,Di ^[1] ; Guang-Yu,Liu ^[1] ; Ke-Da,Yu ^[1] ; Lei,Fan ^[1] ; Jun-Jie,Li ^[1] ; Yi-Feng,Hou ^[1] ; Zhen,Hu ^[1] ; Can-Ming,Chen ^[1] ; Xiao-Yan,Huang ^[1] ; A-Yong,Cao ^[1] ; Xin,Hu ^[1] ; Shen,Zhao ^[1] ; Xiao-Yan,Ma ^[1] ; Ying,Xu ^[1] ; Xiang-Jie,Sun ^[2] ; Wen-Jun,Chai ^[3] ; Xiaomao,Guo ^[4] ; Xizi,Chen ^[5] ; Yanhui,Xu ^[5] ; Xiao-Yu,Zhu ^[6] ; Jian-Jun,Zou ^[6] ; Wen-Tao,Yang ^[2] ; Zhong-Hua,Wang ^[1] ; Zhi-Ming,Shao ^[1]

作者单位： Key Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai Medical College of Fudan University, Shanghai, China.;Department of Oncology, Shanghai Medical College of Fudan University, Shanghai, China. ^[1] Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai Medical College of Fudan University, Shanghai, China. ^[2] Department of Laboratory Animal Science, Fudan University Shanghai Cancer Center, Shanghai Medical College of Fudan University, Shanghai, China. ^[3] Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai Medical College of Fudan University, Shanghai, China. ^[4] Fudan University Shanghai Cancer Center, Institute of Biomedical Sciences, Shanghai Medical College of Fudan University, Shanghai, China. ^[5] Jiangsu Hengrui Pharmaceuticals Co. Ltd, Shanghai, China. ^[6]

医学主题词白蛋白类(Albumins);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);人类(Humans);吲哚类(Indoles);紫杉酚(Paclitaxel);吡咯类(Pyrroles)

DOI 10.1158/1078-0432.CCR-21-4313

PMID 35247906

发布时间 2023-01-06

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交